LY 191704

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525505

CAS#: 146117-78-4

Description: LY 191704 is a 5α-reductase type 1 inhibitor that has potential for the treatment of disorders associated with the overproduction of dihydrotestosterone such as androgenetic alopecia and prostatic hyperplasia. LY 191704 also has potential in the treatment of acne.

Chemical Structure

img
LY 191704
CAS# 146117-78-4
Instruction

Theoretical Analysis

MedKoo Cat#: 525505
Name: LY 191704
CAS#: 146117-78-4
Chemical Formula: C14H16ClNO
Exact Mass: 249.09
Molecular Weight: 249.740
Elemental Analysis: C, 67.33; H, 6.46; Cl, 14.20; N, 5.61; O, 6.41

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: LY 191704; LY191704; LY-191704.

IUPAC/Chemical Name: Benzo(f)quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, trans-

InChi Key: WQBIOEFDDDEARX-STQMWFEESA-N

InChi Code: InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m0/s1

SMILES Code: O=C1N(C)[C@@]2([H])CCC3=CC(Cl)=CC=C3[C@]2([H])CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 249.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5alpha-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol. 2007 Mar;156(3):428-32. PubMed PMID: 17300229.

2: Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, Russell DW, Schweikert HU. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab. 2002 Dec;87(12):5401-7. PubMed PMID: 12466325.

3: Guarna A, Occhiato EG, Scarpi D, Zorn C, Danza G, Comerci A, Mancina R, Serio M. Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6. PubMed PMID: 10714498.

4: Farid NA, Coleman NL. High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY191704, a human type 1 5 alpha-reductase inhibitor, in plasma. J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):212-6. PubMed PMID: 9140778.

5: Farid NA, Schreiner KM, Coleman NL, Van Lier RB, Wrighton SA. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996 Oct;24(10):1162-5. PubMed PMID: 8894520.

6: Neubauer BL, Gray HM, Hanke CW, Hirsch KS, Hsiao KC, Jones CD, Kumar MV, Lawhorn DE, Lindzey J, McQuaid L, Tindall DJ, Toomey RE, Yao RC, Audia JE. LY191704 inhibits type I steroid 5 alpha-reductase in human scalp. J Clin Endocrinol Metab. 1996 Jun;81(6):2055-60. PubMed PMID: 8964828.

7: Hirsch KS, Jones CD, Audia JE, Andersson S, McQuaid L, Stamm NB, Neubauer BL, Pennington P, Toomey RE, Russell DW. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5277-81. PubMed PMID: 8389478; PubMed Central PMCID: PMC46699.